Cerebral Arteriovenous Malformations, Ruptured or Unruptured Cerebral Arteriovenous Malformations
Conditions
Brief summary
The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.
Interventions
None listed
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
0 Years to No maximum
Inclusion criteria
* Patient over 18 years old * Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring * Express consent to participate in the study And * children * Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority
Exclusion criteria
* Patient benefiting from a legal protection measure * Pregnant or breast feeding woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic | 6 months | associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome |
| Associaton between dosage of platelet and the arteriovenous malformation pronostic | 6 months | Dosage of platelet in blood samples and correlation with clinical outcome |
| Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic | 6 months | Dosage of neutrophilic in blood samples and correlation with clinical outcome |
| Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic | 6 months | Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome |
Countries
France
Contacts
Primary ContactAmélie Yavchitz
Backup ContactJean Philippe DESILLES
Outcome results
None listed